Although mortality in patients with systemic lupus erythematosus (SLE) has decreased over the past three decades, infectious complications remain a significant cause of morbidity and mortality, accounting for approximately 20- 50% of all deaths. The profound influence of genetic background on susceptibility to infections has been well established. Recently, specific variants in the tumor necrosis factor alpha (TNFalpha) promoter and the genes encoding Fcgamma receptors and mannose binding lectin have been associated with an increased susceptibility to infections in certain populations. Polymorphisms affecting these same genes have also been associated with an increased risk of developing SLE or expression of specific lupus manifestations. However, the link between these genetic polymorphisms and risk of infections in SLE patients has never been examined.
The aims of this study are: a) to determine the incidence of specific polymorphisms in the TNFalpha promoter and the genes encoding Fcgamma receptors and mannose binding lectin in SLE patients b) characterize the frequency, type and severity of infectious complications in a group of SLE patients as compared with controls c) determine whether the presence of one or more polymorphisms in the genes of interest is associated with an increased risk of infectious complications in SLE. One hundred and five SLE patients and controls matched for age, sex and ethnicity will be assessed over an 18-month period to determine the incidence and severity of infectious complications. The incidence of genetic polymorphisms affecting these candidate genes and the frequency of infections will be compared between the two groups to determine the level of risk. The identification of genetic markers that would distinguish SLE patients at increased risk for infection would make a profound impact on the outcome of this disease by allowing clinicians to institute appropriate prophylactic therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Comprehensive Center (P60)
Project #
5P60AR020614-23
Application #
6310359
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Project Start
1977-09-20
Project End
2001-12-31
Budget Start
Budget End
Support Year
23
Fiscal Year
2000
Total Cost
$116,317
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Wu, Jianming; Xie, Fenglong; Qian, Kun et al. (2011) FAS mRNA editing in Human Systemic Lupus Erythematosus. Hum Mutat 32:1268-77
Wang, Feng; Ezell, Scharri J; Zhang, Yong et al. (2010) FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs 28:234-41
Wang, Wei; Rayburn, Elizabeth R; Velu, Sadanandan E et al. (2009) In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res 15:3511-8
Wang, Wei; Rayburn, Elizabeth R; Zhao, Yuqing et al. (2009) Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett 278:241-248
Wang, Wei; Rayburn, Elizabeth R; Hang, Jie et al. (2009) Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer 65:306-11
Wang, Wei; Rayburn, Elizabeth R; Hao, Miao et al. (2008) Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 68:809-19
Annis, Douglas S; Gunderson, Kristin A; Mosher, Deane F (2007) Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations. J Biol Chem 282:27067-75
Rayburn, Elizabeth R; Wang, Wei; Zhang, Ruiwen et al. (2007) Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 30:1511-9
Wang, Hui; Rayburn, Elizabeth R; Wang, Wei et al. (2006) Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther 5:2106-14
Annis, D S; Murphy-Ullrich, J E; Mosher, D F (2006) Function-blocking antithrombospondin-1 monoclonal antibodies. J Thromb Haemost 4:459-68

Showing the most recent 10 out of 145 publications